| Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ... New England Journal of Medicine 361 (10), 947-957, 2009 | 10059 | 2009 |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ... The Lancet 372 (9652), 1809-1818, 2008 | 1737 | 2008 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically … M Fukuoka, YL Wu, S Thongprasert, P Sunpaweravong, SS Leong, ... Journal of clinical oncology 29 (21), 2866-2874, 2011 | 1726 | 2011 |
| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1344 | 2021 |
| Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial JY Douillard, FA Shepherd, V Hirsh, T Mok, MA Socinski, R Gervais, ... J clin Oncol 28 (5), 744-752, 2010 | 624 | 2010 |
| Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study S Kudoh, H Kato, Y Nishiwaki, M Fukuoka, K Nakata, Y Ichinose, ... American journal of respiratory and critical care medicine 177 (12), 1348-1357, 2008 | 488 | 2008 |
| Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck JSW Stewart, EEW Cohen, L Licitra, CML Van Herpen, C Khorprasert, ... Journal of clinical oncology 27 (11), 1864-1871, 2009 | 435 | 2009 |
| Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or … M Piccart-Gebhart, E Holmes, J Baselga, E De Azambuja, AC Dueck, ... Journal of Clinical Oncology 34 (10), 1034, 2016 | 428 | 2016 |
| Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non–small-cell lung cancer (INVITE): A randomized, phase II study L Crinò, F Cappuzzo, P Zatloukal, M Reck, M Pesek, JC Thompson, ... Journal of Clinical Oncology 26 (26), 4253-4260, 2008 | 271 | 2008 |
| Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced … S Thongprasert, E Duffield, N Saijo, YL Wu, JCH Yang, DT Chu, M Liao, ... Journal of thoracic oncology 6 (11), 1872-1880, 2011 | 164 | 2011 |
| Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance status G Goss, D Ferry, R Wierzbicki, SA Laurie, J Thompson, B Biesma, ... Journal of Clinical Oncology 27 (13), 2253, 2009 | 155 | 2009 |
| Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with … M Fukuoka, Y Wu, S Thongprasert, C Yang, D Chu, N Saijo, C Watkins, ... Journal of Clinical Oncology 27 (15_suppl), 8006-8006, 2009 | 119 | 2009 |
| Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial W Shi, T Jiang, P Nuciforo, C Hatzis, E Holmes, N Harbeck, C Sotiriou, ... Annals of oncology 28 (1), 128-135, 2017 | 68 | 2017 |
| Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) J Douillard, V Hirsh, TS Mok, MA Socinski, C Watkins, E Lowe, A Armour, ... Journal of Clinical Oncology 26 (15_suppl), 8001-8001, 2008 | 56 | 2008 |
| The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer AA Armour, CL Watkins European Respiratory Review 19 (117), 186-196, 2010 | 55 | 2010 |
| A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer HKM Vollan, OM Rueda, SF Chin, C Curtis, G Turashvili, S Shah, ... Molecular oncology 9 (1), 115-127, 2015 | 53 | 2015 |
| No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation RJ Mairs, SH Cunningham, J Russell, A Armour, J Owens, K McKellar, ... Journal of Nuclear Medicine 36 (6), 1088-1095, 1995 | 52 | 1995 |
| Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials FA Shepherd, J Douillard, M Fukuoka, N Saijo, S Kim, T Cufer, MV Sellers, ... Journal of Clinical Oncology 27 (15_suppl), 8011-8011, 2009 | 47 | 2009 |
| The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro A Armour, SH Cunningham, MN Gaze, TE Wheldon, RJ Mairs British journal of cancer 75 (4), 470-476, 1997 | 45 | 1997 |
| A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck JS Stewart, E Cohen, L Licitra, C Van Herpen, C Khorprasert, D Soulieres, ... Cancer Research 67 (9_Supplement), 3522-3522, 2007 | 36 | 2007 |
Prof David R. FerryVP-Gastrointestinal OncologyVerified email at lilly.com
